page_title: Teva Pharmaceuticals
section_title: Research and development
hierarchical_section_title: Teva Pharmaceuticals / Research and development
caption_attribution_description: English: syringe and box of copaxone
context_page_description: Teva Pharmaceutical Industries Ltd., also known as Teva Pharmaceuticals, is an American Israeli pharmaceutical company with dual headquarters in Petah Tikva, Israel and Parsippany, New Jersey, U.S. It specializes primarily in generic drugs, but other business interests include active pharmaceutical ingredients and, to a lesser extent, proprietary pharmaceuticals. It is the largest generic drug manufacturer in the world and one of the 15 largest pharmaceutical companies worldwide.
  Teva's facilities are located in Israel, North America, Europe, Australia, and South America. Teva shares are listed on the Tel Aviv Stock Exchange. The company is a member of the Pharmaceutical Research and Manufacturers of America.
context_section_description: Teva holds patents on multiple drugs, including: Copaxone, a specialty drug (for the treatment of multiple sclerosis), now the world's best selling MS drug, and Azilect (sold as Agilect in some countries) for treatment of Parkinson's disease. By July 2015, Copaxone held a "31.2 percent shares of total MS prescriptions in the United States." Teva's new 40 mg version of Copaxone taken three times a week "accounted for 68.5 percent of total Copaxone prescriptions in the United States." Copaxone accounts for about fifty percent of "Teva's profit and 20 percent of revenue." Competitors' Glatopa, 20 mg version of Copaxone, is taken once a day.
  In June 2006, Teva received from the FDA a 180-day exclusivity period to sell simvastatin (Zocor) in the U.S. as a generic drug in all strengths except 80 mg. Teva presently competes with the maker of brand-name Zocor, Merck & Co.; Ranbaxy Laboratories, which has 180-day exclusivity for the 80 mg strength; and Dr. Reddy's Laboratories, whose authorized generic version (licensed by Merck) is exempt from exclusivity.
  In June 2010, the company announced it would discontinue its production of propofol, a major sedative estimated to be used in 75% of all US anesthetic procedures.
  In March 2015, Teva sold four anti-cancer compounds to Ignyta Inc. for $41.6 million. As part of the deal Teva sold the following compounds which were then renamed:
  CEP-32496 (renamed RXDX-105) a small molecule inhibitor of BRAF, EGFR and RET, now in Phase I/II trials
  CEP-40783 (renamed RXDX-106) a small molecule inhibitor of AXL and c-Met in preclinical development
  CEP-40125 (renamed RXDX-107) a nanoformulation of a modified bendamustine with potenital activity in solid tumours. Bendamustine Rapid Infusion as therapy for CLL and NHL is part of Teva's specialty drugs pipeline.
  TEV-44229 (renamed RXDX-108) a potent inhibitor of the kinase PKCiota
  In July 2019, the company stopped production of Vincristine, a critical drug used to treat the most common forms of childhood cancer, and was criticized by media for creating a worldwide shortage of the drug. On 28 January 2020, the company announced that the Food and Drug Administration (FDA) had approved an autoinjector device for Ajovy (fremanezumab-vfrm) injection.
caption: Copaxone, a Teva patented drug
exif: {"Image Make": "Canon", "Image Model": "Canon EOS DIGITAL REBEL XT", "Image Orientation": "Horizontal (normal)", "Image XResolution": "300", "Image YResolution": "300", "Image ResolutionUnit": "Pixels/Inch", "Image Software": "Adobe Photoshop CS Windows", "Image DateTime": "2008:10:06 09:48:21", "Image YCbCrPositioning": "Co-sited", "Image ExifOffset": "232", "Thumbnail Compression": "JPEG (old-style)", "Thumbnail XResolution": "72", "Thumbnail YResolution": "72", "Thumbnail ResolutionUnit": "Pixels/Inch", "Thumbnail JPEGInterchangeFormat": "1058", "Thumbnail JPEGInterchangeFormatLength": "5277", "EXIF ExposureTime": "1/50", "EXIF FNumber": "5", "EXIF ExposureProgram": "Program Normal", "EXIF ISOSpeedRatings": "800", "EXIF ExifVersion": "0221", "EXIF DateTimeOriginal": "2008:09:11 08:22:23", "EXIF DateTimeDigitized": "2008:09:11 08:22:23", "EXIF ComponentsConfiguration": "YCbCr", "EXIF ShutterSpeedValue": "92469/16384", "EXIF ApertureValue": "76085/16384", "EXIF ExposureBiasValue": "0", "EXIF MeteringMode": "Pattern", "EXIF Flash": "Flash did not fire, compulsory flash mode", "EXIF FocalLength": "27", "EXIF FlashPixVersion": "0100", "EXIF ColorSpace": "sRGB", "EXIF ExifImageWidth": "600", "EXIF ExifImageLength": "419", "Interoperability InteroperabilityIndex": "R98", "Interoperability InteroperabilityVersion": "[48, 49, 48, 48]", "EXIF InteroperabilityOffset": "932", "EXIF FocalPlaneXResolution": "1728000/437", "EXIF FocalPlaneYResolution": "384000/97", "EXIF FocalPlaneResolutionUnit": "2", "EXIF CustomRendered": "Normal", "EXIF ExposureMode": "Auto Exposure", "EXIF WhiteBalance": "Auto", "EXIF SceneCaptureType": "Standard"}